Surgery Timing for Colorectal Cancer That Has Spread to the Liver
Compares removing the bowel cancer and liver spots in one operation or two.
Plain-language title generated from the registry record
Registry title: Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
Key facts
- Where
- Oslo, NorwaySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06200831, who can take part
Where in Norway
- Oslo University HospitalOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT06200831
- Record updated
- 16 October 2026
- Original description
The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases. This is an investigator-initiated, multicentre, randomized controlled trial to assess complications (primary endpoint), survival, cost-effectiveness, and quality of life (secondary endpoints).This trial will include patients with resectable primary tumour in the colon or upper rectum with less than five liver metastases that is possible to treat with surgical resection and/or ablation (RFA/MWA) at time of evaluation.Read full original descriptionShow less
Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases - A Multicentre Randomized Controlled Trial
The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases. This is an investigator-initiated, multicentre, randomized controlled trial to assess complications (primary endpoint), survival, cost-effectiveness, and quality of life (secondary endpoints).This trial will include patients with resectable primary tumour in the colon or upper rectum with less than five liver metastases that is possible to treat with surgical resection and/or ablation (RFA/MWA) at time of evaluation.
Inclusion: Age 18-80 years old; Both CRC and liver metastases in situ at time of evaluation; Resectable primary tumor in the colon or upper rectum; Less than 5 liver metastases, evaluated by the multidisciplinary tumor board meeting as possible to treat with surgical resection and/or ablation (RFA/MWA).
Exclusion: Primary tumor in the lower rectum with indication for abdominoperineal resection; Liver resection requiring resection of more than 2 adjacent segments (Couinaud); Liver metastases planned treated with irreversible electroporation (IRE); Perforation or major bleeding from the primary tumor; Unresectable primary tumor; Locally advanced primary tumor (T4); Acute or imminent bowel obstruction; Pre-treatment of the primary tumor with a colon stent; Non-resectable lung metastases; Metastases outside of liver (besides resectable lung metastases); Eastern Cooperative Oncology Group (ECOG) Performance status ≥ 3.